- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Alzheimer's Disease
Volume 2012 (2012), Article ID 383796, 12 pages
The Alzheimer's Amyloid-Degrading Peptidase, Neprilysin: Can We Control It?
1School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
2I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, RAS, 44 Thorez Avenue, Saint Petersburg 194223, Russia
Received 15 February 2012; Accepted 1 June 2012
Academic Editor: Fabrizio Tagliavini
Copyright © 2012 N. N. Nalivaeva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The amyloid cascade hypothesis of Alzheimer's disease (AD) postulates that accumulation in the brain of amyloid β-peptide (Aβ) is the primary trigger for neuronal loss specific to this pathology. In healthy brain, Aβ levels are regulated by a dynamic equilibrium between Aβ release from the amyloid precursor protein (APP) and its removal by perivascular drainage or by amyloid-degrading enzymes (ADEs). During the last decade, the ADE family was fast growing, and currently it embraces more than 20 members. There are solid data supporting involvement of each of them in Aβ clearance but a zinc metallopeptidase neprilysin (NEP) is considered as a major ADE. NEP plays an important role in brain function due to its role in terminating neuropeptide signalling and its decrease during ageing or after such pathologies as hypoxia or ischemia contribute significantly to the development of AD pathology. The recently discovered mechanism of epigenetic regulation of NEP by the APP intracellular domain (AICD) opens new avenues for its therapeutic manipulation and raises hope for developing preventive strategies in AD. However, consideration needs to be given to the diverse physiological roles of NEP. This paper critically evaluates general biochemical and physiological functions of NEP and their therapeutic relevance.
The amyloid cascade hypothesis of Alzheimer’s disease (AD) was originally proposed 20 years ago [1, 2], and during this period it has significantly influenced development of AD-related research. Although it provided a huge amount of data confirming that the accumulation of the amyloid -peptide (A), especially A, is directly linked to the development of neurodegeneration, it also to some extent detracted attention from understanding the normal physiological role both of A and its precursor protein, APP. Recently, several attempts have been made to reevaluate the amyloid hypothesis and to suggest new directions in AD research [3–5]. Although our knowledge of the processes involved in A production is rather extensive this has not resulted in any viable therapy despite several promising trials of inhibitors preventing A formation . Moreover, during the last two decades, A toxicity was studied and reexamined in various animal and cellular models suggesting that the toxic A species might be represented by oligomers rather than monomers, fibrils, or plaques [7, 8], and much research has been devoted to the search for pharmacological approaches to prevent A oligomerization as a therapy in AD .
One of the important concepts developed from the amyloid cascade hypothesis is the realisation that amyloid metabolism is a dynamic process represented by production of A (by - and -secretases) and its removal from the brain (via perivascular or enzymatic mechanisms) rather than an irreversible pathway of its accumulation leading to cell death and cognitive impairment. As such the enzymes capable of degrading A became a major research and therapeutic target [10–12]. Evaluation of the normal physiological role of A suggests that complete elimination of A from the brain would not be a target in AD therapy since it most likely has a normal physiological role as a regulatory peptide or even as a transcription factor [13–16]. However, by manipulating its levels through improved perivascular drainage or proteolytic degradation might help to prevent accumulation of harmful amyloid species causing cell death and AD pathology [12, 17]. One of the amyloid-degrading enzymes, neprilysin (NEP), has been the main target of our research over many years, and in this paper we will summarize current knowledge of this metallopeptidase and mechanisms to manipulate its activity in disease states.
2. General Properties of NEP
Neutral endopeptidase, or neprilysin (NEP), was first described as a neutral proteinase in rat kidney brush border membranes and then purified from rabbit kidney and characterised as a zinc metallopeptidase . Although NEP is abundant in the kidney (about 4% of all membrane proteins), its content in other organs, including the brain, is much lower. NEP was later rediscovered as a brain enzyme responsible for inactivation of the enkephalin family of neuropeptides and given the name enkephalinase . However, it was subsequently shown that NEP is not enkephalin-specific but that it can cleave a wide range of biologically relevant peptide substrates, for example, substance P, and as such it was given the common name, endopeptidase-24.11 . In the literature, NEP is also known as the common acute lymphoblastic leukaemia antigen (CALLA or CD10) since it turned out to be identical with this leukocyte cell surface antigen , although to date the substrate(s) and functions of NEP in the immune system have not been identified. NEP was also reported to be identical with a recently described activity termed skin fibroblast elastase which plays a role in skin aging and UVA-induced skin damage .
NEP is an oligopeptidase which cleaves peptides containing up to 40–50 amino acids and the most efficiently hydrolyzed substrate is substance P . NEP substrate specificity is rather wide but those for which NEP action has a physiological role in metabolism are rather limited. The principal substrates of NEP in vivo appear to be enkephalins, atrial natriuretic peptide, tachykinins, bradykinin, endothelins, adrenomedullin, members of the vasoactive intestinal peptide family, glucagon, thymopentin, and, most significantly in pathophysiological terms, the Alzheimer’s disease Aβ peptide.
NEP is a type II integral membrane zinc metalloprotein and does not have a proenzyme form. It is an ectoenzyme with the bulk of its structure, including the active site, facing the extracellular space. Depending on tissue source the of NEP ranges from about 85, 000 to 110, 000 due to differences in its glycosylation . The cDNA cloning of NEP revealed that rat and human enzymes consist of 742 amino acids . The high similarity between human and rodent NEP proteins makes the rat a useful animal model for studying NEP functions and regulation. To date, there are only few characterised endogeneous tissue specific inhibitors of NEP. The first, isolated from bovine spinal cord, was a heptapeptide spinorphin which also inhibited dipeptidyl peptidases and angiotensin-converting enzyme . A decade later, Rougeot and colleagues discovered sialorphin, an exocrine and endocrine signaling mediator, synthesized mostly in the submandibular gland and prostate of rats . The first human NEP inhibitor isolated from saliva was opiorphin which had some pain-suppressive potency . The most potent and widely used NEP inhibitors include phosphoramidon and thiorphan, and the 3D structure of the extracellular domain of NEP in a complex with phosphoramidon has been resolved allowing better understanding of the catalytic properties of the enzyme . One particular feature of the NEP catalytic site is its restricted size which prevents access of large peptides and proteins but allows peptides containing up to 50 amino acid residues. This is consistent with A as a preferred substrate of NEP. Another characteristic feature of NEP is its sensitivity to inhibition by phosphoramidon and thiorphan at nanomolar concentrations. Although a closely related NEP homologue endothelin-converting enzyme (ECE-1) is also inhibited by phosphoramidon, it is only sensitive to micromolar concentrations of the inhibitor and is not affected by thiorphan.
Despite being originally considered as a unique mammalian membrane endopeptidase, it was subsequently demonstrated that the human genome contains at least seven NEP-like enzymes. This metallopeptidase family is even more abundant in Drosophila melanogaster (24 predicted members) and Caenorhabditis elegans (22 members), and phosphoramidon-sensitive activities have been identified in these species [30, 31] which makes them useful models for studying functional properties of NEP. In the brain, NEP levels are much lower than in the kidney, and it appears to have mostly neuronal localisation  although it was recently reported to be expressed by activated astrocytes  and microglia . In peripheral tissues NEP was also found to be transiently expressed on the surface of certain haematopoietic cells and increased NEP levels were found on mature lymphocytes in certain disease states (for review see ). It has also been implicated in the progression of a number of cancers, including prostate , renal , and lung  cancer. Another important role of NEP is related to inactivation of the natriuretic peptides in vivo and as such NEP inhibitors have been explored as potential cardiovascular and renal therapeutics.
The human NEP gene is located on chromosome 3 and exists in a single copy which spans more than 80 kb. It is composed of 24 exons and is highly conserved among mammalian species . Expression of the NEP gene is controlled through two distinct promoters  whose role differs between cell types, although both promoters show similar characteristics and activity. Three distinct NEP mRNAs have been identified in human and rat which differ only in their 5′-noncoding regions [39, 40]. A gene knockout of NEP in mice has been reported in which the animals appeared developmentally normal but the NEP null mice were highly sensitive to endotoxic shock . This observation may reflect a general role of NEP in the metabolism of proinflammatory peptides. NEP knockout mice also showed enhanced aggressive behaviour in the resident-intruder paradigm and altered locomotor activity as assessed in the photobeam system . They also had an increased alcohol and food consumption .
3. NEP and Neuronal Functions
In the brain, NEP is mainly located on neuronal cells, especially in the striatonigral pathway , although it is also present in the hippocampus, where it functions to inactivate somatostatin, and in cortical regions . Pre- and postsynaptic localization of NEP in the nervous system further emphasizes its important role in neuronal function  and this is schematically reflected in Figure 1. The enzyme has also been found in Schwann cells in the peripheral nervous system . The significant increase in the expression of NEP by Schwann cells after axonal damage suggests that this enzyme could play a role in axonal regeneration .
The functional role of NEP in the brain is primarily determined by the physiological properties of its substrates and the roles they play in the nervous system (see Table 1). As such NEP was linked to such brain functions as LTP, synaptic plasticity, motor functions and locomotion, memory, anxiety, pain, hyperalgesia, circadian rhythms, sleep, fatigue, water homeostasis, blood-brain barrier integrity, and neuroinflammation. It plays a certain role in stroke pathology , pathophysiology of itch , attenuates central functions of baroreceptors , food intake, hormonal release, cardiovascular regulation, thermoregulation, stress , and anxiolytic response . It also participates in dendrite elongation and the maturation of dendritic spines . NEP was also suggested to play a major role in nociception activating the initial stage of nociceptin metabolism at the spinal cord level . A role for NEP in memory has been confirmed in our experiments with i.c. injections of its inhibitors (phosphoramidon and thiorphan) to rats resulting in disruption of memory and neuronal plasticity [56–60]. In addition to these important neuronal functions of NEP, it is also now considered as a major amyloid-degrading enzyme and mechanisms of its regulation and reactivation have been extensively studied in the last decade . Although the precise physiological properties of Aβ peptides are still far from being fully understood, the accumulating evidence suggests that they can act as modulators of neuronal function and synaptic plasticity  and the role of NEP in regulating concentrations of Aβ at functional levels can be important for normal brain activity.
4. NEP and Amyloid Metabolism
The ability of neprilysin to catabolise -amyloid peptide was first demonstrated in vitro by Howell and colleagues  and then confirmed in vivo [83, 84]. It was demonstrated that NEP knockout mice have increased levels of A peptides in the brain and administration of the neprilysin inhibitor thiorphan to rats led to increased A levels [83, 85]. On the contrary, NEP gene transfer to AD transgenic mice was able to reverse amyloid-like pathology and improve animal behaviour [86–88]. Importantly, it was shown that NEP is the most potent A-degrading enzyme in the brain  and can degrade not only monomeric forms of A but also its more toxic oligomers . N-terminally truncated forms of A (Ax-42) and pyroglutamyl modified A are also major contributors to the amyloid pathology of AD due to their abundance in AD brain and their cell toxicity . Although the pyroglutamyl A species have increased resistance to degradation by aminopeptidases , the comparative susceptibility of these peptides to NEP activity has not been adequately quantified to date.
Studies both in vivo and in vitro have now strongly linked NEP with the pathogenesis of AD and made it a viable therapeutic target. Further in vivo studies, including our own work, have indeed demonstrated that NEP mRNA, protein and activity levels decline with age in the cortex and hippocampus of rodents and humans [58–60, 93, 94] and also are reduced in the AD brain . Decreased NEP levels and activity were also reported under such pathological conditions leading to AD, as ischemia or hypoxia [33, 93]. Our studies also demonstrated that prenatal hypoxia leads to reduced NEP protein and activity levels in the cortex and hippocampus of rats during their postnatal life [58–60].
Decreased NEP expression in the vasculature was also suggested to be responsible for the development of cerebral amyloid angiopathy found in AD patients . However, along with the age-related and pathology-induced decrease of NEP expression seen in neuronal cells, it was reported that NEP is upregulated in reactive astrocytes surrounding amyloid plaques in AD transgenic mice which could contribute to some compensatory mechanisms . On the contrary, Hickman and colleagues have reported an age-dependent decline of NEP and other amyloid-degrading enzyme expression in microglia resulting in decreased Aβ clearance . Apart from the decline in NEP expression, age-related decrease of NEP capability to degrade Aβ might be due to enzyme oxidation  or conformational inactivation, for example, by amyloid peptide .
In addition to NEP, its homologue, neprilysin-2 (NEP2), was also characterised in the brain . Although NEP2 is the closest NEP homologue, it has different properties, in particular, in cellular localization. NEP2 has two alternatively spliced forms, one of which is a soluble secreted form, also known as soluble, secreted endopeptidase (SEP) . In the CNS, NEP2 is mainly localized in the cortex and hippocampus and is characteristic to specific neuronal populations [100, 102]. Despite the fact that NEP2 has a broad repertoire of substrates, its physiological role, apart from in male fertility, still is largely unknown. NEP2 was shown to degrade Aβ in vitro [89, 103] and recently Hafez and colleagues using gene knockout and transgenic animals have demonstrated that NEP2 contributes to A degradation in vivo . Recently it was demonstrated that NEP2 and NEP mRNA expression is altered in the AD-susceptible brain areas of patients with MCI compared to nonimpaired subjects. Moreover, NEP2 enzymatic activity in the mid-temporal and mid-frontal gyri of MCI and AD subjects was lower compared to controls and was associated with the level of cognitive decline . However, at present, mechanisms of NEP2 cell specificity and regulation of its expression and activity have not been sufficiently addressed and further studies are required to estimate the role of this NEP homologue in pathogenesis of AD and to estimate its therapeutic value.
5. Modulation of Neprilysin Expression
Reports on age- and AD-related NEP decline have induced an intensive search for means to upregulate NEP gene expression and enzyme activity. NEP gene delivery studies have suggested that not only intracerebral injections of NEP-bearing constructs can have an antiamyloid effect in AD animal models  but that intraperitoneal injections of a lentivirus vector expressing NEP fused with the ApoB transport domain could also reduce A burden and increase synaptic density in the brain of AD transgenic mice . This opened up the development of non-invasive therapeutic approaches for potential treatment in patients with AD. One such approach has utilised a novel system for injection of an NEP coding plasmid into skeletal muscle via a syringe electrode . Injected in this way, hNEP was detected in the muscle, serum, and brain of treated mice even 30 days after injection with minimal damage at the site of electrotransfer. Another, ex vivo NEP gene delivery method, was also suggested by Selkoe and colleagues who implanted primary fibroblasts, expressing a secreted form of NEP, into the brain of APP transgenic mice which induced robust clearance of amyloid plaques at the site of engraftment . An interesting approach based on the observation that brain and plasma A are in equilibrium through transport mechanisms  was developed by Hersh and colleagues, who found that in AD transgenic mice overexpressing NEP in erythrocytes or leukocytes there was a reduced A burden in the brain [110, 111]. An alternative strategy of expressing a secreted, soluble form of NEP in the plasma through an adenovirus construct was also effective in clearing brain A yet did not affect the plasma levels of other peptide substrates of NEP such as bradykinin or substance P . Expressing NEP in plasma in this way could also provide a simple but effective system to maintain and monitor long-term activity of this amyloid-β-degrading peptidase. Along with developing methods of NEP upregulation, the optimal timing of NEP overexpression has also been examined suggesting that earlier upregulation of NEP levels was more beneficial in alleviating symptoms in a mouse model of AD .
Apart from targeted gene delivery, strategies for pharmacological NEP regulation have also been intensively studied in the last ten years. Cell culture studies have demonstrated that NEP activity can be increased by, among other compounds, a component of green tea extract, EGCG  and other plant extracts and polyphenols (e.g., ). Saido and colleagues have suggested that elevated levels of NEP substrates could upregulate NEP by a feedback control mechanism . However, after screening a wide range of NEP neuropeptide substrates, they have found that only somatostatin was capable of upregulating NEP activity in primary neuronal cells. They have also suggested a possible mechanism of NEP activation involving somatostatin receptor subtypes 2 or 4, but these studies have not resulted in any further development of somatostatin receptor agonists for therapeutic application in AD. A 24-residue peptide, humanin, originally isolated from the brain of an AD patient, which has neuroprotective properties and decreases brain A levels in animal models, was shown to mediate its A-lowering effects by increasing NEP expression levels and could also provide a strategy for enhancing amyloid clearance . Another receptor-mediated mechanism for pharmacological upregulation of NEP is the peroxisome proliferator activated receptor-δ (PPARδ) whose selective agonist, GW742, was shown to activate the NEP promoter driving luciferase expression in transfected HEK293 cells .
A completely new direction of studies linking the amyloid cascade hypothesis and NEP to the pathogenesis of AD has emerged from studies of the role of the C-terminal APP intracellular domain (AICD), released by -secretase activity, in the regulation of NEP transcription . AICD is an approximately 6 kDa peptide which is present as a number of species of which the major form is 50 amino acids long but AICD48 and 51 species are also detectable [120, 121]. It is still unclear whether all of the isoforms of AICD are equally competent in transcriptional regulation. Despite being controversial and disputed by some other authors (e.g., [122–124]), the role of AICD in regulation of NEP has been confirmed by demonstrating that AICD binds to the NEP promoter in neuronal cells expressing high levels of NEP while in low NEP expressing cells, the NEP promoter is repressed by histone deacetylases (HDACs) . This AICD activating effect was shown to be cell specific and even cell age dependent which may explain some of the contradictions in the literature [126–128]. Moreover, it was established that formation of transcriptionally active AICD depends on the particular APP isoform expressed (specifically APP695) and requires the active -secretase (amyloidogenic) pathway [126, 129]. Apart from NEP, AICD activates expression of several genes and their number is steadily increasing [130, 131]. An important functional link confirming the role of AICD and gene activation was reported by Xu and colleagues  who found that AICD binds the MED12 unit of the mediator RNA polymerase II complex. This finding confirms AICD transcriptional activity  and validates other AICD-dependent genes such as aquaporin-1, MICAL2, and fibronectin-1 .
The fact that NEP gene expression is repressed in neuronal cells via competitive binding of HDACs to its promoter  has prompted us to look at the HDAC inhibitors which might reactivate NEP gene expression. As we have found in human neuroblastoma SH-SY5Y cells, trichostatin was able to activate NEP expression at the mRNA and protein levels and also increase its activity. More important from the therapeutic point of view was our observation that a clinically available antiepileptic drug valproic acid (VA) was also able to activate the NEP gene not only in cellular but in animal models as well [59, 125]. Moreover, injections of VA to AD transgenic mice were shown to decrease amyloid-related toxicity and improve animal behaviour although the authors had not considered to analyse levels of NEP expression and activity in their paradigm . Our own animal studies have further demonstrated that administration of VA to rats with reduced levels of NEP expression in the brain due to prenatal hypoxia resulted in increased NEP activity in the cortex and hippocampus and improvement of animal short-term memory  which can be linked with the role of NEP in dendritic spine formation and restoration of neuronal circuits [59, 60]. The role of histone modifications in downregulation of the NEP promoter under hypoxic conditions has also been demonstrated by Wang and colleagues in primary cortical neuronal cells who demonstrated that NEP mRNA levels could be restored by VA administration to cells prior to hypoxia . These studies revise the role of such a widely used antiepileptic drug as VA in regulation of neuronal gene expression and its protective role in neurodegeneration . However, they also underlie the necessity for design of more specific HDAC inhibitors for targeted activation of NEP or other neuronal and, specifically, AD-related genes. Indeed, a recent report specified that inhibitors of class 1 HDACs reverse contextual memory deficits in an AD-mouse model . This opens an avenue for retrospective analysis of the effect of VA or other HDAC inhibitors on development of AD.
Another therapeutically approved compound which was shown to modulate NEP expression via AICD-dependent mechanisms is the tyrosine kinase inhibitor, Gleevec (imatinib, STI-571), which was shown to elevate AICD levels and increase NEP mRNA and protein levels . Although other authors failed to support this observation , recent work by Bauer and colleagues clearly demonstrated that the imatinib- (Gleevec-) induced NEP increase is APP and AICD dependent .
Importantly, in prostate cancer, NEP expression is downregulated by extensive hypermethylation of the promoter region and reexpression of neprilysin by treating the animals with the demethylating agent 5-aza-2′-deoxycytidine was able to inhibit tumor formation in the prostates of athymic mice [139, 140]. According to our data, downregulation of NEP in neuronal cells is not due to hypermethylation of its promoter and cannot be reactivated by 5-aza-2′-deoxycytidine which confirms cell specificity of NEP gene regulation .
As mentioned above, green tea extracts EFLA85942 and EGCG increase NEP expression and activity in human neuroblastoma SH-SY5Y, SK-N-SH, and NB7 cells ( and our own unpublished data). Extending these studies to animal models, we have found that prolonged EGCG administration to rats via osmotic minipumps was able to increase NEP activity in hypoxic rats to the levels recorded in control age-matched animals. Moreover, administration of EGCG has also improved performance of animals in the radial maze and improvement of short-term and long-term memory in the novel object recognition test . This further supports the role of NEP in memory and extends the list of biologically active compounds which might be beneficial for prevention of cognitive deficit characteristic to AD pathology (Figure 2).
6. Concluding Remarks
Twenty years on from the formulation of the amyloid cascade hypothesis, there have been no successful clinical trials in AD. Several reasons for this can be suggested, for example, initiation of trials in patients in which neuronal loss and damage is already too far advanced, emphasizing the need for early diagnosis and good biomarkers. Also, late onset disease may well reflect defects in clearance mechanisms for A rather than in the enhanced synthesis which occurs in early onset cases . Hence, strategies to promote clearance, such as elevation of NEP expression and activity, may represent new opportunities for therapeutic intervention, either alone or in combination with other strategies. As follows from the detailed analysis of NEP properties and function, this enzyme plays an important role in brain function and disruption of its natural metabolic roles leads to various pathological conditions both centrally and in the periphery. Upregulation of NEP expression in such diseases as AD or prostate cancer has already been shown to be beneficial in animal models and various approaches have now been developed to activate this enzyme in cells and organisms. The discovery of epigenetic and pharmacological mechanisms for controlling NEP activity suggests a possibility for design of a preventive therapeutic strategy in AD and other age-related human diseases. Taking into account the wide substrate repertoire of NEP, there might be a cohort of functions which can be maintained by NEP modulators such as learning and memory, pain and inflammation, depression and anxiety, and further research of the precise molecular mechanisms involved in tissue and cell-specific regulation of this peptidase might give us a powerful tool to improve human health and wellbeing.
|AICD:||APP intracellular domain|
|APP:||Amyloid precursor protein|
|PKC:||Protein kinase C|
|PPAR:||Peroxisome proliferator-activated receptor|
|SNP:||Single nucleotide polymorphism|
The authors thank the U.K. Medical Research Council, Alzheimer’s Research UK, Russian Foundation for Basic Research (RFBR 10-04-01156), and the Programme of RAS “Fundamental Sciences for Medicine” for financial support for this work.
- J. A. Hardy and G. A. Higgins, “Alzheimer's disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992.
- D. J. Selkoe, “The molecular pathology of Alzheimer's disease,” Neuron, vol. 6, no. 4, pp. 487–498, 1991.
- J. Hardy, “The amyloid hypothesis for Alzheimer's disease: a critical reappraisal,” Journal of Neurochemistry, vol. 110, no. 4, pp. 1129–1134, 2009.
- R. J. Castellani and M. A. Smith, “Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’,” Journal of Pathology, vol. 224, no. 2, pp. 147–152, 2011.
- A. Goate and J. Hardy, “Twenty years of Alzheimer's disease-causing mutations,” Journal of Neurochemistry, vol. 120, supplement 1, pp. 3–8, 2012.
- E. Karran, M. Mercken, and B. de Strooper, “The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 698–712, 2011.
- S. Li, M. Jin, T. Koeglsperger, N. E. Shepardson, G. M. Shankar, and D. J. Selkoe, “Soluble a β oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors,” Journal of Neuroscience, vol. 31, no. 18, pp. 6627–6638, 2011.
- M. E. Larson and and S. E. Lesné, “Soluble Aβ oligomer production and toxicity,” Journal of Neurochemistry, vol. 120, supplement 1, pp. 125–139, 2012.
- P. S. Aisen, “The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors,” CNS Drugs, vol. 19, no. 12, pp. 989–996, 2005.
- J. S. Miners, N. Barua, P. G. Kehoe, et al., “Aβ-degrading enzymes: potential for treatment of Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 70, no. 11, pp. 944–959, 2011.
- N. N. Nalivaeva, L. R. Fisk, N. D. Belyaev, and A. J. Turner, “Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease,” Current Alzheimer Research, vol. 5, no. 2, pp. 212–224, 2008.
- N. N. Nalivaeva, C. Beckett, N. D. Belyaev, and A. J. Turner, “Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?” Journal of Neurochemistry, vol. 120, supplement 1, pp. 167–185, 2012.
- H. A. Pearson and C. Peers, “Physiological roles for amyloid β peptides,” Journal of Physiology, vol. 575, no. 1, pp. 5–10, 2006.
- J. Hardy, “Does Aβ 42 have a function related to blood homeostasis?” Neurochemical Research, vol. 32, no. 4-5, pp. 833–835, 2007.
- Y. Ohyagi, H. Asahara, D. H. Chui et al., “Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease,” The FASEB Journal, vol. 19, no. 2, pp. 255–257, 2005.
- J. A. Bailey, B. Maloney, Y. W. Ge, and D. K. Lahiri, “Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis,” Gene, vol. 488, no. 1-2, pp. 13–22, 2011.
- C. A. Hawkes, W. Härtig, J. Kacza et al., “Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy,” Acta Neuropathologica, vol. 121, no. 4, pp. 431–443, 2011.
- M. A. Kerr and A. J. Kenny, “The purification and specificity of a neutral endopeptidase from rabbit kidney brush border,” Biochemical Journal, vol. 137, no. 3, pp. 477–488, 1974.
- B. Malfroy, J. P. Swerts, A. Guyon, et al., “High affinity enkephalin degrading peptidase in brain is increased after morphine,” Nature, vol. 276, no. 5687, pp. 523–526, 1978.
- R. Matsas, I. S. Fulcher, A. J. Kenny, and A. J. Turner, “Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 10 I, pp. 3111–3115, 1983.
- M. Letarte, S. Vera, R. Tran et al., “Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase,” Journal of Experimental Medicine, vol. 168, no. 4, pp. 1247–1253, 1988.
- N. Morisaki, S. Moriwaki, Y. Sugiyama-Nakagiri, K. Haketa, Y. Takema, and G. Imokawa, “Neprilysin is identical to skin fibroblast elastase: its role in skin aging and UV responses,” The Journal of Biological Chemistry, vol. 285, no. 51, pp. 39819–39827, 2010.
- R. Matsas, A. J. Kenny, and A. J. Turner, “The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11,” Biochemical Journal, vol. 223, no. 2, pp. 433–440, 1984.
- J. M. Relton, N. S. Gee, R. Matsas, A. J. Turner, and A. J. Kenny, “Purification of endopeptidase-24.11 (“enkephalinase”) from pig brain by immunoadsorbent chromatography,” Biochemical Journal, vol. 215, no. 3, pp. 519–523, 1983.
- B. Malfroy, W. J. Kuang, P. H. Seeburg, A. J. Mason, and P. R. Schofield, “Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase),” The FEBS Letters, vol. 229, no. 1, pp. 206–210, 1988.
- K. Nishimura, M. Ueki, H. Kaneto, and T. Hazato, “Study of a new endogenous inhibitor of enkephalin-degrading enzymes; pharmacological function and metabolism of spinorphin,” Japanese Journal of Anesthesiology, vol. 42, no. 11, pp. 1663–1670, 1993.
- C. Rougeot, M. Messaoudi, V. Hermitte et al., “Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8549–8554, 2003.
- A. Wisner, E. Dufour, M. Messaoudi et al., “Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 47, pp. 17979–17984, 2006.
- C. Oefner, A. D'Arcy, M. Hennig, F. K. Winkler, and G. E. Dale, “Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon,” Journal of Molecular Biology, vol. 296, no. 2, pp. 341–349, 2000.
- A. J. Turner, R. E. Isaac, and D. Coates, “The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function,” Bioassay, vol. 23, no. 3, pp. 261–269, 2001.
- N. D. Bland, J. W. Pinney, J. E. Thomas, A. J. Turner, and R. E. Isaac, “Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships,” BMC Evolutionary Biology, vol. 8, no. 1, article 16, 2008.
- K. Barnes, A. J. Turner, and A. J. Kenny, “An immunoelectron microscopic study of pig substantia nigra shows co-localization of endopeptidase-24.11 with substance P,” Neuroscience, vol. 53, no. 4, pp. 1073–1082, 1993.
- L. Fisk, N. N. Nalivaeva, J. P. Boyle, C. S. Peers, and A. J. Turner, “Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes,” Neurochemical Research, vol. 32, no. 10, pp. 1741–1748, 2007.
- S. E. Hickman, E. K. Allison, and J. El Khoury, “Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer's disease mice,” Journal of Neuroscience, vol. 28, no. 33, pp. 8354–8360, 2008.
- T. W. LeBien and R. T. McCormack, “The common acute lymphoblastic leukemia antigen (CD10). Emancipation from a functional enigma,” Blood, vol. 73, no. 3, pp. 625–635, 1989.
- C. N. Papandreou, B. Usmani, Y. P. Geng et al., “Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression,” Nature Medicine, vol. 4, no. 1, pp. 50–57, 1998.
- B. Göhring, H. J. Holzhausen, A. Meye et al., “Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer,” International Journal of Molecular Medicine, vol. 2, no. 4, pp. 409–414, 1998.
- A. J. Cohen, P. A. Bunn, W. Franklin et al., “Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux,” Cancer Research, vol. 56, no. 4, pp. 831–839, 1996.
- L. D'Adamio, M. A. Shipp, E. L. Masteller, and E. L. Reinherz, “Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5′ untranslated regions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 18, pp. 7103–7107, 1989.
- C. Li, R. M. Booze, and L. B. Hersh, “Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs,” The Journal of Biological Chemistry, vol. 270, no. 11, pp. 5723–5728, 1995.
- B. Lu, N. P. Gerard, L. F. Kolakowski et al., “Neutral endopeptidase modulation of septic shock,” Journal of Experimental Medicine, vol. 181, no. 6, pp. 2271–2275, 1995.
- H. S. Fischer, G. Zernig, R. Schuligoi et al., “Alterations within the endogenous opioid system in mice with targeted deletion of the neutral endopeptidase (“enkephalinase”) gene,” Regulatory Peptides, vol. 96, no. 1-2, pp. 53–58, 2000.
- W. E. Siems, B. Maul, W. Krause et al., “Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice,” European Journal of Pharmacology, vol. 397, no. 2-3, pp. 327–334, 2000.
- K. Barnes, R. Matsas, N. M. Hooper, A. J. Turner, and A. J. Kenny, “Endopeptidase-24.11 is striosomally ordered in pig brain and, in contrast to aminopeptidase N and peptidyl dipeptidase A (“angiotensin converting enzyme”), is a marker for a set of striatal efferent fibres,” Neuroscience, vol. 27, no. 3, pp. 799–817, 1988.
- K. Barnes, S. Doherty, and A. J. Turner, “Endopeptidase-24.11 is the integral membrane peptidase initiating degradation of somatostatin in the hippocampus,” Journal of Neurochemistry, vol. 64, no. 4, pp. 1826–1832, 1995.
- K. Barnes, A. J. Turner, and A. J. Kenny, “Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry,” Journal of Neurochemistry, vol. 58, no. 6, pp. 2088–2096, 1992.
- C. Kioussi and R. Matsas, “Endopeptidase-24.11, a cell-surface peptidase of central nervous system neurons, is expressed by Schwann cells in the pig peripheral nervous system,” Journal of Neurochemistry, vol. 57, no. 2, pp. 431–440, 1991.
- C. Kioussi, A. Mamalaki, K. Jessen, R. Mirsky, L. B. Hersh, and R. Matsas, “Expression of endopeptidase-24.11 (common acute lymphoblastic leukaemia antigen CD10) in the sciatic nerve of the adult rat after lesion and during regeneration,” European Journal of Neuroscience, vol. 7, no. 5, pp. 951–961, 1995.
- Z. Wang, D. Yang, X. Zhang et al., “Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and Hippocampal neurons,” PLoS ONE, vol. 6, no. 4, Article ID e19229, 2011.
- Y. G. Sun and Z. F. Chen, “A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord,” Nature, vol. 448, no. 7154, pp. 700–703, 2007.
- D. I. Diz, M. A. Garcia-Espinosa, P. E. Gallagher, D. Ganten, C. M. Ferrario, and D. B. Averill, “Angiotensin-(1–7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats,” Journal of Cardiovascular Pharmacology, vol. 51, no. 6, pp. 542–548, 2008.
- A. P. Silva, C. Cavadas, and E. Grouzmann, “Neuropeptide Y and its receptors as potential therapeutic drug targets,” Clinica Chimica Acta, vol. 326, no. 1-2, pp. 3–25, 2002.
- J. Hernández, A. B. Segarra, M. Ramírez et al., “Stress influences brain enkephalinase, oxytocinase and angiotensinase activities: a new hypothesis,” Neuropsychobiology, vol. 59, no. 3, pp. 184–189, 2009.
- C. Gandou, A. Ohtani, K. Senzaki, and T. Shiga, “Neurotensin promotes the dendrite elongation and the dendritic spine maturation of the cerebral cortex in vitro,” Neuroscience Research, vol. 66, no. 3, pp. 246–255, 2010.
- C. Sakurada, S. Sakurada, T. Orito, K. Tan-No, and T. Sakurada, “Degradation of nociceptin (orphanin FQ) by mouse spinal cord synaptic membranes is triggered by endopeptidase-24.11: an in vitro and in vivo study,” Biochemical Pharmacology, vol. 64, no. 8, pp. 1293–1303, 2002.
- N. M. Dubrovskaya, N. N. Nalivaeva, S. A. Plesneva, A. A. Feponova, A. J. Turner, and I. A. Zhuravin, “Changes in the activity of amyloid-degrading metallopeptidases leads to disruption of memory in rats,” Neuroscience and Behavioral Physiology, vol. 40, no. 9, pp. 975–980, 2010.
- N. M. Dubrovskaya, N. N. Nalivaeva, D. S. Vasilev, et al., “Mechanisms of short-term working memory deficit,” in Short-Term Memory: New Research, Nova Science, New York, NY, USA, 2012.
- N. N. Nalivaeva, N. D. Belyaev, D. I. Lewis et al., “Effect of sodium valproate administration on brain neprilysin expression and memory in rats,” Journal of Molecular Neuroscience, vol. 46, no. 3, pp. 569–577, 2012.
- N. N. Nalivaeva, N. M. Dubrovskaya, D. S. Vasiliev, et al., “Changes in the activity of amyloid-degrading enzymes affect cognitive functions in rats via alteration of the synaptopodin-positive dendritic network,” in New Frontiers in Molecular Mechanisms in Neurological and Psychiatric Disorders, E. Babusikova, D. Dobrota, J. Lehotsky, Martin, and Slovakia, Eds., vol. 1, pp. 277–285, 2011.
- I. A. Zhuravin, N. M. Dubrovskaya, D. S. Vasilev, N. L. Tumanova, and N. N. Nalivaeva, “Epigenetic and pharmacological regulation of the amyloid-degrading enzyme neprilysin results in modulation of cognitive functions in mammals,” Doklady Biological Sciences, vol. 438, no. 1, pp. 145–148, 2011.
- E. Abramov, I. Dolev, H. Fogel, G. D. Ciccotosto, E. Ruff, and I. Slutsky, “Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses,” Nature Neuroscience, vol. 12, no. 12, pp. 1567–1576, 2009.
- Y. Harigai, M. Natsume, F. Li, A. Ohtani, K. Senzaki, and T. Shiga, “Differential roles of calcitonin family peptides in the dendrite formation and spinogenesis of the cerebral cortex in vitro,” Neuropeptides, vol. 45, no. 4, pp. 263–272, 2011.
- A. P. Fernández, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martínez, “Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12581–12586, 2008.
- T. Ma and E. Klann, “Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease,” Journal of Neurochemistry, vol. 120, supplement 1, pp. 140–148, 2011.
- H. S. Fischer, G. Zernig, K. F. Hauser, C. Gerard, L. B. Hersh, and A. Saria, “Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide,” Journal of Molecular Neuroscience, vol. 18, no. 1-2, pp. 129–134, 2002.
- Y. B. Wang, C. Peng, and Y. H. Liu, “Low dose of bradykinin selectively increases intracellular calcium in glioma cells,” Journal of the Neurological Sciences, vol. 258, no. 1-2, pp. 44–51, 2007.
- S. Arora and Anubhuti, “Role of neuropeptides in appetite regulation and obesity—a review,” Neuropeptides, vol. 40, no. 6, pp. 375–401, 2006.
- T. Ogawa, S. Kiryu-Seo, M. Tanaka et al., “Altered expression of neprilysin family members in the pituitary gland of sleep-disturbed rats, an animal model of severe fatigue,” Journal of Neurochemistry, vol. 95, no. 4, pp. 1156–1166, 2005.
- C. Schwarzer, “30 years of dynorphins—new insights on their functions in neuropsychiatric diseases,” Pharmacology and Therapeutics, vol. 123, no. 3, pp. 353–370, 2009.
- B. Song and J. C. G. Marvizón, “Peptidases prevent μ-opioid receptor internalization in dorsal horn neurons by endogenously released opioids,” Journal of Neuroscience, vol. 23, no. 5, pp. 1847–1858, 2003.
- B. P. Roques, F. Noble, V. Daugé, M. C. Fournie-Zaluski, and A. Beaumont, “Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology,” Pharmacological Reviews, vol. 45, no. 1, pp. 87–146, 1993.
- H. H. Wang, H. L. Hsieh, and C. M. Yang, “Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9,” Journal of Cellular Physiology, vol. 226, no. 9, pp. 2244–2256, 2011.
- K. L. Gamble, T. Kudo, C. S. Colwell, and D. G. McMahon, “Gastrin-releasing peptide modulates fast delayed rectifier potassium current in Per1-expressing SCN neurons,” Journal of Biological Rhythms, vol. 26, no. 2, pp. 99–106, 2011.
- C. Viollet, G. Lepousez, C. Loudes, C. Videau, A. Simon, and J. Epelbaum, “Somatostatinergic systems in brain: networks and functions,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. 75–87, 2008.
- H. H. Krämer, L. He, B. Lu, F. Birklein, and C. Sommer, “Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase,” Neurobiology of Disease, vol. 35, no. 2, pp. 177–183, 2009.
- T. M. Loonam, P. A. H. Noailles, J. Yu, J. P. Q. Zhu, and J. A. Angulo, “Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum,” Life Sciences, vol. 73, no. 6, pp. 727–739, 2003.
- J. P. Huston, R. U. Hasenöhrl, F. Boix, P. Gerhardt, and R. K. W. Schwarting, “Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity,” Psychopharmacology, vol. 112, no. 2-3, pp. 147–162, 1993.
- R. U. Hasenöhrl, M. A. D. Souza-Silva, S. Nikolaus et al., “Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery,” Neuropeptides, vol. 34, no. 5, pp. 272–280, 2000.
- S. McLean, “Do substance P and the NK1 receptor have a role in depression and anxiety?” Current Pharmaceutical Design, vol. 11, no. 12, pp. 1529–1547, 2005.
- J. Yamaoka and S. Kawana, “Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice,” Journal of Dermatological Science, vol. 48, no. 2, pp. 123–132, 2007.
- A. T. L. Hughes, C. Guilding, and H. D. Piggins, “Neuropeptide signaling differentially affects phase maintenance and rhythm generation in SCN and extra-SCN circadian oscillators,” PLoS ONE, vol. 6, no. 4, Article ID e18926, 2011.
- S. Howell, J. Nalbantoglu, and P. Crine, “Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism,” Peptides, vol. 16, no. 4, pp. 647–652, 1995.
- N. Iwata, S. Tsubuki, Y. Takaki et al., “Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition,” Nature Medicine, vol. 6, no. 2, pp. 143–150, 2000.
- Y. Takaki, N. Iwata, S. Tsubuki et al., “Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain,” Journal of Biochemistry, vol. 128, no. 6, pp. 897–902, 2000.
- N. Iwata, S. Tsubuki, Y. Takaki et al., “Metabolic regulation of brain Aβ by neprilysin,” Science, vol. 292, no. 5521, pp. 1550–1552, 2001.
- E. Hama, K. Shirotani, H. Masumoto, Y. Sekine-Aizawa, H. Aizawa, and T. C. Saido, “Clearance of extracellular and cell-associated amyloid β peptide through viral expression of neprilysin in primary neurons,” Journal of Biochemistry, vol. 130, no. 6, pp. 721–726, 2001.
- R. A. Marr, E. Rockenstein, A. Mukherjee et al., “Neprilysin gene transfer reduces human amyloid pathology in transgenic mice,” Journal of Neuroscience, vol. 23, no. 6, pp. 1992–1996, 2003.
- B. Spencer, R. A. Marr, E. Rockenstein et al., “Long-term neprilysin gene transfer is associated with reduced levels of intracellular Aβ and behavioral improvement in APP transgenic mice,” BMC Neuroscience, vol. 9, article 109, 2008.
- K. Shirotani, S. Tsubuki, N. Iwata et al., “Neprilysin degrades both amyloid β peptides 1–40 and 1–42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 21895–21901, 2001.
- H. Kanemitsu, T. Tomiyama, and H. Mori, “Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form,” Neuroscience Letters, vol. 350, no. 2, pp. 113–116, 2003.
- S. Jawhar, O. Wirths, and T. A. Bayer, “Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease,” The Journal of Biological Chemistry, vol. 286, no. 45, pp. 38825–38832, 2011.
- S. C. Drew, C. L. Masters, and K. J. Barnham, “Alzheimer's Aβ peptides with disease-associated NTerminal modifications: Influence of isomerisation, truncation and mutation on Cu2+ coordination,” PLoS ONE, vol. 5, no. 12, Article ID e15875, 2010.
- N. N. Nalivaeva, L. Fisk, E. G. Kochkina et al., “Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes,” Annals of the New York Academy of Sciences, vol. 1035, pp. 21–33, 2004.
- A. Caccamo, S. Oddo, M. C. Sugarman, Y. Akbari, and F. M. LaFerla, “Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders,” Neurobiology of Aging, vol. 26, no. 5, pp. 645–654, 2005.
- D. S. Wang, R. B. Lipton, M. J. Katz et al., “Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 5, pp. 378–385, 2005.
- M. Carpentier, Y. Robitaille, L. DesGroseillers, G. Boileau, and M. Marcinkiewicz, “Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 10, pp. 849–856, 2002.
- J. Apelt, K. Ach, and R. Schliebs, “Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques,” Neuroscience Letters, vol. 339, no. 3, pp. 183–186, 2003.
- D. S. Wang, N. Iwata, E. Hama, T. C. Saido, and D. W. Dickson, “Oxidized neprilysin in aging and Alzheimer's disease brains,” Biochemical and Biophysical Research Communications, vol. 310, no. 1, pp. 236–241, 2003.
- V. B. Dorfman, L. Pasquini, M. Riudavets et al., “Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease,” Neurobiology of Aging, vol. 31, no. 10, pp. 1743–1757, 2010.
- O. Tanja, P. Facchinetti, C. Rose, M. C. Bonhomme, C. Gros, and J. C. Schwartz, “Neprilysin II: a putative novel metalloprotease and its isoforms in CNS and testis,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 565–570, 2000.
- K. Ikeda, N. Emoto, S. B. Raharjo et al., “Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides,” The Journal of Biological Chemistry, vol. 274, no. 45, pp. 32469–32477, 1999.
- P. Facchinetti, C. Rose, J. C. Schwartz, and T. Ouimet, “Ontogeny, regional and cellular distribution of the novel metalloprotease neprilysin 2 in the rat: a comparison with neprilysin and endothelin-converting enzyme-1,” Neuroscience, vol. 118, no. 3, pp. 627–639, 2003.
- J. Y. Huang, A. M. Bruno, C. A. Patel et al., “Human membrane metallo-endopeptidase-like protein degrades both β-amyloid 42 and β-amyloid 40,” Neuroscience, vol. 155, no. 1, pp. 258–262, 2008.
- D. Hafez, J. Y. Huang, A. M. Huynh et al., “Neprilysin-2 is an important β-amyloid degrading enzyme,” American Journal of Pathology, vol. 178, no. 1, pp. 306–312, 2011.
- J. Y. Huang, D. M. Hafez, B. D. James, et al., “Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 28, no. 2, pp. 433–441, 2012.
- B. Spencer, R. A. Marr, R. Gindi et al., “Peripheral delivery of a CNS targeted, metalo-protease reduces Aβ toxicity in a mouse model of Alzheimer's disease,” PLoS ONE, vol. 6, no. 1, Article ID e16575, 2011.
- Y. Li, J. Wang, J. Liu, and F. Liu, “A novel system for in vivo neprilysin gene delivery using a syringe electrode,” Journal of Neuroscience Methods, vol. 193, no. 2, pp. 226–231, 2010.
- M. L. Hemming, M. Patterson, C. Reske-Nielsen, L. Lin, O. Isacson, and D. J. Selkoe, “Reducing amyloid plaque burden via ex vivo gene delivery of an Aβ-degrading protease: a novel therapeutic approach to Alzheimer disease,” PLoS Medicine, vol. 4, no. 8, article e262, 2007.
- R. Deane, Z. Wu, and B. V. Zlokovic, “RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier,” Stroke, vol. 35, no. 11, pp. 2628–2631, 2004.
- Y. Liu, H. Guan, T. L. Beckett et al., “In vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes,” Peptides, vol. 28, no. 12, pp. 2348–2355, 2007.
- H. Guan, Y. Liu, A. Daily et al., “Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease,” Journal of Neuroscience Research, vol. 87, no. 6, pp. 1462–1473, 2009.
- Y. Liu, C. Studzinski, T. Beckett, M. P. Murphy, R. L. Klein, and L. B. Hersh, “Circulating neprilysin clears brain amyloid,” Molecular and Cellular Neuroscience, vol. 45, no. 2, pp. 101–107, 2010.
- S. S. El-Amouri, H. Zhu, J. Yu, R. Marr, I. M. Verma, and M. S. Kindy, “Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease,” American Journal of Pathology, vol. 172, no. 5, pp. 1342–1354, 2008.
- M. F. Melzig and M. Janka, “Enhancement of neutral endopeptidase activity in SK-N-SH cells by green tea extract,” Phytomedicine, vol. 10, no. 6-7, pp. 494–498, 2003.
- A. Kiss, J. Kowalski, and M. F. Melzig, “Effect of Epilobium angustifolium L. extracts and polyphenols on cell proliferation and neutral endopeptidase activity in selected cell lines,” Pharmazie, vol. 61, no. 1, pp. 66–69, 2006.
- T. Sãito, N. Iwata, S. Tsubuki et al., “Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation,” Nature Medicine, vol. 11, no. 4, pp. 434–439, 2005.
- T. Niikura, E. Sidahmed, C. Hirata-Fukae, P. S. Aisen, and Y. Matsuoka, “A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice,” PLoS ONE, vol. 6, no. 1, Article ID e16259, 2011.
- S. Kalinin, J. C. Richardson, and D. L. Feinstein, “A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease,” Current Alzheimer Research, vol. 6, no. 5, pp. 431–437, 2009.
- R. Pardossi-Piquard, A. Petit, T. Kawarai et al., “Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP,” Neuron, vol. 46, no. 4, pp. 541–554, 2005.
- C. Yu, S. H. Kim, T. Ikeuchi et al., “Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment γ: evidence for distinct mechanisms involved in γ-secretase processing of the APP and Notch1 transmembrane domains,” The Journal of Biological Chemistry, vol. 276, no. 47, pp. 43756–43760, 2001.
- T. Sato, N. Dohmae, Y. Qi et al., “Potential link between amyloid β-protein 42 and C-terminal fragment γ 49–99 of β-amyloid precursor protein,” The Journal of Biological Chemistry, vol. 278, no. 27, pp. 24294–20301, 2003.
- A. C. Chen and D. J. Selkoe, “Response to: Pardossi-Piquard etal., “Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP.” Neuron 46, 541–554,” Neuron, vol. 53, no. 4, pp. 479–483, 2007.
- S. S. Hébert, L. Serneels, A. Tolia et al., “Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes,” EMBO Reports, vol. 7, no. 7, pp. 739–745, 2006.
- E. Waldron, S. Isbert, A. Kern et al., “Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription,” Experimental Cell Research, vol. 314, no. 13, pp. 2419–2433, 2008.
- N. D. Belyaev, N. N. Nalivaeva, N. Z. Makova, and A. J. Turner, “Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease,” EMBO Reports, vol. 10, no. 1, pp. 94–100, 2009.
- N. D. Belyaev, K. A. B. Kellett, C. Beckett et al., “The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a β-secretase-dependent pathway,” The Journal of Biological Chemistry, vol. 285, no. 53, pp. 41443–41454, 2010.
- C. Bauer, R. Pardossi-Piquard, J. Dunys, et al., “β-secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by Imatinib,” Journal of Alzheimer's Disease, vol. 27, no. 3, pp. 511–520, 2011.
- Y. Hong, C. Beckett, N. D. Belyaev, and A. J. Turner, “The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells,” International Journal of Cancer, vol. 130, no. 4, pp. 775–786, 2012.
- Z. V. Goodger, L. Rajendran, A. Trutzel, B. M. Kohli, R. M. Nitsch, and U. Konietzko, “Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway,” Journal of Cell Science, vol. 122, no. 20, pp. 3703–3714, 2009.
- D. Aydin, M. A. Filippov, J. A. Tschäpe et al., “Comparative transcriptome profiling of amyloid precursor protein family members in the adult cortex,” BMC Genomics, vol. 12, article 160, 2011.
- R. Pardossi-Piquard and F. Checler, “The physiology of the β-amyloid precursor protein Intracellular domain AICD,” Journal of Neurochemistry, vol. 120, supplement 1, pp. 109–124, 2012.
- X. Xu, H. Zhou, and T. G. Boyer, “Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling,” EMBO Reports, vol. 12, no. 3, pp. 216–222, 2011.
- A. J. Turner, N. D. Belyaev, and N. N. Nalivaeva, “Mediator: the missing link in amyloid precursor protein nuclear signalling,” EMBO Reports, vol. 12, no. 3, pp. 180–181, 2011.
- H. Qing, G. He, P. T. T. Ly et al., “Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models,” Journal of Experimental Medicine, vol. 205, no. 12, pp. 2781–2789, 2008.
- N. N. Nalivaeva, N. D. Belyaev, and A. J. Turner, “Sodium valproate: an old drug with new roles,” Trends in Pharmacological Sciences, vol. 30, no. 10, pp. 509–514, 2009.
- M. Kilgore, C. A. Miller, D. M. Fass et al., “Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease,” Neuropsychopharmacology, vol. 35, no. 4, pp. 870–880, 2010.
- Y. S. Eisele, M. Baumann, B. Klebl, C. Nordhammer, M. Jucker, and E. Kilger, “Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-β degrading enzyme neprilysin,” Molecular Biology of the Cell, vol. 18, no. 9, pp. 3591–3600, 2007.
- M. C. Vázquez, L. M. Vargas, N. C. Inestrosa, and A. R. Alvarez, “C-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis,” Journal of Cellular Physiology, vol. 220, no. 1, pp. 136–143, 2009.
- B. A. Usmani, R. Shen, M. Janeczko et al., “Methylation of the neutral endopeptidase gene promoter in human prostate cancers,” Clinical Cancer Research, vol. 6, no. 5, pp. 1664–1670, 2000.
- J. Dai, R. Shen, M. Sumitomo et al., “Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells,” Clinical Cancer Research, vol. 7, no. 5, pp. 1370–1377, 2001.
- E. Hama and T. C. Saido, “Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid β peptide,” Medical Hypotheses, vol. 65, no. 3, pp. 498–500, 2005.